Acer Therapeutics Inc (ACER) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ACER Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Acer Therapeutics Inc balances growth, leverage, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent0.59
Cash & Short-term Investments0.00
Inventories5.20
Deferred Offering Costs DE0.00
Other Current Assets0.01
Prepaid Expense, Current AS0.33
Total Current Assets6.14
Equipment/Property/Plant Net0.04
Goodwill net7.65
Other Assets, Noncurrent0.17
Total Assets14.00
Liabilities
Accounts Payable, Current AC7.01
Accrued Liabilities, Current AC5.07
Short-term Debt13.55
Other Liabilities, Current36.05
Total Current Liabilities61.67
Convertible Notes Payable, Noncurrent LO0.00
Total Long-term Debt0.00
Other liabilities, Noncurrent0.08
Term Loans Payable Current At Fair Value Current18.15
Promissory Notes Payable Current1.02
Total Liabilities61.75
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock132.10
Retained Earnings / Accumulated Deficit-179.85
Other Equity0.00
Common Stockholder's Equity-47.74
Total Stockholder's Equity-47.74
Liabilities & Stockholder's Equity14.00
4 historic quarters locked

Sign in to unlock the full Acer Therapeutics Inc balance sheet history.

About Acer Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-23-065159

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.